Hillgene chooses Wallonia for its European cell therapy operations
Hillgene, a Chinese company specialising in the production of cell therapies, has set its sights on Liège for its European branch.
This strategic decision is part of the growing development of Wallonia's biotechnology ecosystem, attracting major players in the global biopharmaceutical sector.
A location at the heart of innovation
Hillgene's arrival in Liège promises to be a significant addition to the local biotechnology ecosystem. The Chinese company, an expert in cell therapies, chose the GiGA buildings, which are part of the university hospital, as its site. This strategic choice will enable Hillgene to enjoy an environment conducive to innovation while establishing close links with the region's academic and scientific community.
World-renowned expertise
As a Contract Development and Manufacturing Organization (CDMO), Hillgene has already successfully completed over 30 cell therapy projects worldwide and supported eight investigational medicine applications in China. This solid expertise positions the company as a partner of choice for laboratories and biopharmaceutical companies seeking to develop and produce innovative cell therapies.
A strategic partnership with Wallonia
The decision to set up its European office in Liège stems from a strategic partnership with Wallonia, facilitated by the Wallonia Export-Investment Agency (AWEX) and Bridge to Health (B2H), Liège's life sciences hub. This collaboration demonstrates Wallonia's growing appeal to international biotechnology companies, which are attracted by the rich life sciences ecosystem and the opportunities for collaboration with local players.
A promising start and prospects for growth
Hillgene envisages a modest start-up in the GIGA buildings, relying on the Cell and Gene Therapy Laboratory (LTCG) to produce therapies for customers, including Chinese companies wanting to conduct clinical trials in Europe. This strategy will enable Hillgene to connect with the local research ecosystem while using the LTCG's GMP pharmaceutical-standard production facilities.
Strengthening the Walloon biomanufacturing cluster
Hillgene's move to Liège will strengthen Wallonia's biomanufacturing cluster for cell and gene therapy, reinforcing the region's position on the European and global stage. This strategic decision will help to boost the local biotechnology ecosystem and create new opportunities for collaboration and development in cell therapy.
Hillgene's arrival in Wallonia marks an important milestone in the development of the Walloon biotechnology ecosystem, demonstrating the region's growing attractiveness to international biopharmaceutical companies.
This move promises not only to strengthen the Walloon biomanufacturing cluster for cell and gene therapy but also to stimulate innovation and collaboration in the life sciences.
You want to set up and increase your biopharmaceutical business in Wallonia, like Hillgene did?
Our sectorial business specialists will help you, at every step of your project, to set up easily your business in Wallonia.
